We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes (Revised)
Read MoreHide Full Article
One of the world’s largest medical technology, services and solutions companies, Medtronic plc (MDT - Free Report) has been consistently expanding in the field of diabetes management. Keeping in line with this, the company recently inked a new ‘outcomes-based’ collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections. This agreement aims at measuring health outcomes for patients who have switched to pump therapy with Medtronic insulin pump. This insulin pump features Medtronic’s SmartGuard Technology, including the new MiniMed 670G system.
This tie-up gives Aetna members access to Medtronic’s advanced diabetes technologies and support system, along with the new MiniMed 670G system. This partnership will help the company to demonstrate the improved patient outcome at lower costs.
According to Medtronic, “The agreement ties a component of Medtronic’s reimbursement to successfully meeting agreed-upon clinical improvement thresholds for Aetna members with type 1 and type 2 diabetes who chooses to transition from multiple daily injections to a Medtronic insulin pump.” This is aimed at enhancing patient experience, improving clinical outcomes and cutting down on the total cost of care.
In this regard, we note that Medtronic launched MiniMed 670G system this June, a Hybrid Closed Loop insulin delivery system for type 1 diabetic patients. This followed the U.S. FDA approval received late last year. MiniMed 670G helps Medtronic simplify and improve diabetes management through advancement of smart algorithms that help control glucose levels in diabetic patients.
We expect the latest development by Medtronic to be completely strategic taking into consideration the hugely expanding market of diabetes management. According to BCC Research, the global diabetes market should reach a worth of $155 billion by 2021, at a CAGR of 4.4% in the 2016 to 2021 period. Clearly, the company has bountiful opportunities in this niche market.
Also, over the last six months, Medtronic has outperformed the Zacks categorized Medical Product industry. As per the last share price movement, the company has gained 24.8%, compared to the 20.7% gain of the broader industry.
Recent Developments
Of late, Medtronic has been making efforts to strengthen its diabetes business in Canada. The company announced that its subsidiary has opened its first Canadian Medtronic Resource Centre to serve diabetic patients in Surrey BC and nearby.
Zacks Rank and Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Inogen sports a Zacks Rank #1 (Strong Buy), while Align Technology and Accelerate Diagnostics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 33.6% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 22.5% over the last three months.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has added roughly 15.8% over the last three months.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
(We are reissuing this article to correct a mistake. The original article, issued on Jun 27, 2017, should no longer be relied upon.)
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes (Revised)
One of the world’s largest medical technology, services and solutions companies, Medtronic plc (MDT - Free Report) has been consistently expanding in the field of diabetes management. Keeping in line with this, the company recently inked a new ‘outcomes-based’ collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections. This agreement aims at measuring health outcomes for patients who have switched to pump therapy with Medtronic insulin pump. This insulin pump features Medtronic’s SmartGuard Technology, including the new MiniMed 670G system.
This tie-up gives Aetna members access to Medtronic’s advanced diabetes technologies and support system, along with the new MiniMed 670G system. This partnership will help the company to demonstrate the improved patient outcome at lower costs.
According to Medtronic, “The agreement ties a component of Medtronic’s reimbursement to successfully meeting agreed-upon clinical improvement thresholds for Aetna members with type 1 and type 2 diabetes who chooses to transition from multiple daily injections to a Medtronic insulin pump.” This is aimed at enhancing patient experience, improving clinical outcomes and cutting down on the total cost of care.
In this regard, we note that Medtronic launched MiniMed 670G system this June, a Hybrid Closed Loop insulin delivery system for type 1 diabetic patients. This followed the U.S. FDA approval received late last year. MiniMed 670G helps Medtronic simplify and improve diabetes management through advancement of smart algorithms that help control glucose levels in diabetic patients.
We expect the latest development by Medtronic to be completely strategic taking into consideration the hugely expanding market of diabetes management. According to BCC Research, the global diabetes market should reach a worth of $155 billion by 2021, at a CAGR of 4.4% in the 2016 to 2021 period. Clearly, the company has bountiful opportunities in this niche market.
Also, over the last six months, Medtronic has outperformed the Zacks categorized Medical Product industry. As per the last share price movement, the company has gained 24.8%, compared to the 20.7% gain of the broader industry.
Recent Developments
Of late, Medtronic has been making efforts to strengthen its diabetes business in Canada. The company announced that its subsidiary has opened its first Canadian Medtronic Resource Centre to serve diabetic patients in Surrey BC and nearby.
Zacks Rank and Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Inogen sports a Zacks Rank #1 (Strong Buy), while Align Technology and Accelerate Diagnostics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 33.6% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 22.5% over the last three months.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has added roughly 15.8% over the last three months.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
(We are reissuing this article to correct a mistake. The original article, issued on Jun 27, 2017, should no longer be relied upon.)